Ankylosing SpondylitisNCT07383805
Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis
An observational study of Ankylosing Spondylitis and AS, run by Assiut University at 1 site in Egypt.
Trial summary
1. To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers. 2. Association of Tim-3 with sacroiliac MRI findings and the hip inflammatory MRI scoring system (HIMRISS) . Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Ankylosing Spondylitis, AS, Tim3
- How many people
- 81 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2026to 1 Sep 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: patients diagnose as ankylosing spondylitis and healthy controls in Assiut university hospital
Adult patients (>18 years) diagnosed as AS according to 2009 ASAS -Classification criteria (8) Exclusion Criteria:-Age below 18 years old. Patients with other autoimmune diseases. infection (cause increase in inflammatory makers) Any patient with ferromagnetic implants or cardiac pacemaker pregnancy Uncontrolled Hypertension renal failure Chronic liver disease Malignancy Diabetes Mellitus
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Expression of T Cell Immunoglobulin and Mucin-domain Containing Molecule 3 (Tim-3) on Neutrophils as an Indicator to Assess Disease Activity in Ankylosing Spondylitis Patients
- To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers.
- Association of Tim-3 with sacroiliac MRI findings and the hip inflammatory MRI scoring system (HIMRISS) .
- Conditions
- Ankylosing Spondylitis, AS, Tim3
- Medical subject headings
- Spondylitis, Ankylosing
What is being measured
The primary outcome is the main question the study is designed to answer.
To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients
investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study start1 Jun 2026 (estimated)
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ankylosing SpondylitisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 81 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eman Safwat Mohamed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07383805
- Sponsor's protocol ID
- Tim-AS
- Status last verified
- Jan 2026
- First submitted
- 16 Jan 2026
- Last updated
- 3 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expression of T Cell Immunoglobulin and Mucin-domain Containing Molecule 3 (Tim-3) on Neutrophils as an Indicator to Assess Disease Activity in Ankylosing Spondylitis Patients
- ClinicalTrials.gov ID
- NCT07383805
- Acronym / sponsor ID
- Tim-AS
- Conditions
- Ankylosing Spondylitis, AS, Tim3
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 81 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Sep 2029 (estimated)
- First posted
- 3 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers.
- Association of Tim-3 with sacroiliac MRI findings and the hip inflammatory MRI scoring system (HIMRISS) .
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- patients diagnose as ankylosing spondylitis and healthy controls in Assiut university hospital
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients
Time frame: through study completion, an average of 1 year
investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Ankylosing Spondylitis
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
Identification of Serum Level of Glutathione Peroxidase 4
Spondyloarthropathy
Not yet recruitingPhase 1
A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Active, not recruitingObservational study
Neuropathic Spinal Pain in Ankylosing Spondylitis
Ankylosing Spondylitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ankylosing Spondylitis and AS, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eman Safwat, MD (01014116158, safwateman605@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026.